Sarah E. S. Leary
Seattle paediatric neuro-oncologist who led COG ACNS0332, the trial that found adding carboplatin to radiotherapy improves survival in children with high-risk group 3 medulloblastoma but isotretinoin does not help.
Overview
Sarah Leary is a paediatric neuro-oncologist at Seattle Children's Hospital and a leader of the Children's Oncology Group brain tumour committee. She was first author of the 2021 JAMA Oncology report of ACNS0332, the randomised trial in high-risk medulloblastoma in which carboplatin given with radiotherapy improved event-free survival in group 3 tumours, while maintenance isotretinoin did not improve outcomes and was stopped early.
Similar pages
not linked directly; found by shared links- PersonJacques Grill
Shares Childhood cancers (all types) and the tags paediatric, brain, trialist.
- PersonGiles W. Robinson
Shares Childhood cancers (all types), Medulloblastoma and the tags paediatric, brain, trialist.
- PersonDarren R. Hargrave
Shares Childhood cancers (all types) and the tags paediatric, brain, trialist.
- PersonAndrew B. Lassman
Shares the tags brain, trialist.
- PersonJan C. Buckner
Shares the tags brain, trialist.
- PersonOlivier L. Chinot
Shares the tags brain, trialist.
- PersonRob Pieters
Shares Childhood cancers (all types) and the tags paediatric, trialist.
- PersonKimberly P. Dunsmore
Shares Childhood cancers (all types) and the tags paediatric, trialist.